| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 03/02/2025 | 13:00 | Business Wire | Surmodics Announces Successful Early Clinical Use of Pounce™ XL Thrombectomy System, Suitable for Non-Surgical Removal of Thrombi and Emboli from Iliac and Femoral Arteries | NASDAQ:SRDX | SurModics Inc |
| 30/01/2025 | 13:55 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:SRDX | SurModics Inc |
| 30/01/2025 | 13:00 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:SRDX | SurModics Inc |
| 30/01/2025 | 13:00 | Business Wire | Surmodics Reports First Quarter of Fiscal Year 2025 Financial Results | NASDAQ:SRDX | SurModics Inc |
| 28/01/2025 | 23:39 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:SRDX | SurModics Inc |
| 22/01/2025 | 23:15 | Edgar (US Regulatory) | Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors | NASDAQ:SRDX | SurModics Inc |
| 19/12/2024 | 14:05 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material | NASDAQ:SRDX | SurModics Inc |
| 19/12/2024 | 14:00 | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements | NASDAQ:SRDX | SurModics Inc |
| 26/11/2024 | 22:53 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:SRDX | SurModics Inc |
| 20/11/2024 | 14:47 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:SRDX | SurModics Inc |
| 14/11/2024 | 21:36 | Edgar (US Regulatory) | Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] | NASDAQ:SRDX | SurModics Inc |
| 06/11/2024 | 13:00 | Business Wire | Surmodics Reports Fourth Quarter and Fiscal Year 2024 Financial Results | NASDAQ:SRDX | SurModics Inc |
| 30/10/2024 | 19:30 | Business Wire | Surmodics Announces Early Results from PROWL Registry Study of Real-World Limb Ischemia Patients Treated with Pounce™ Thrombectomy System | NASDAQ:SRDX | SurModics Inc |
| 01/10/2024 | 13:00 | Business Wire | Surmodics Receives FDA 510(k) Clearance for Pounce™ XL Thrombectomy System, Expanding the Pounce Thrombectomy Platform to Larger Peripheral Arteries up to 10 mm in Diameter | NASDAQ:SRDX | SurModics Inc |
| 31/07/2024 | 13:00 | Business Wire | Surmodics Reports Third Quarter of Fiscal Year 2024 Financial Results | NASDAQ:SRDX | SurModics Inc |
| 08/07/2024 | 22:28 | Edgar (US Regulatory) | Form DEFM14A - Definitive proxy statement relating to merger or acquisition | NASDAQ:SRDX | SurModics Inc |
| 17/06/2024 | 14:08 | PR Newswire (US) | Kuehn Law Encourages, FFNW, HCP, CALB, and SRDX Investors to Contact Law Firm | NASDAQ:SRDX | SurModics Inc |
| 10/06/2024 | 22:57 | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial ownership by individuals | NASDAQ:SRDX | SurModics Inc |
| 10/06/2024 | 13:00 | Business Wire | Surmodics Awarded Thrombectomy Products Agreement with Premier, Inc. | NASDAQ:SRDX | SurModics Inc |
| 30/05/2024 | 00:36 | PR Newswire (US) | ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Surmodics, Inc. | NASDAQ:SRDX | SurModics Inc |
| 29/05/2024 | 13:00 | Business Wire | Surmodics Enters into Definitive Agreement to be Acquired by GTCR for $43.00 Per Share in Cash, Representing an Approximate Equity Value of $627 Million | NASDAQ:SRDX | SurModics Inc |
| 24/05/2024 | 22:01 | Edgar (US Regulatory) | Form SD - Specialized disclosure report | NASDAQ:SRDX | SurModics Inc |
| 01/05/2024 | 13:00 | Business Wire | Surmodics Reports Second Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance | NASDAQ:SRDX | SurModics Inc |
| 19/04/2024 | 13:00 | Business Wire | Surmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1 | NASDAQ:SRDX | SurModics Inc |
| 27/02/2024 | 14:00 | Business Wire | Surmodics to Participate in Upcoming Investor Conferences in March and April | NASDAQ:SRDX | SurModics Inc |
| 09/02/2024 | 17:20 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:SRDX | SurModics Inc |
| 01/02/2024 | 13:00 | Business Wire | Surmodics Reports First Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance | NASDAQ:SRDX | SurModics Inc |
| 22/01/2024 | 13:30 | Business Wire | Surmodics Announces Successful Early Clinical Use of Pounce™ LP (Low Profile) Thrombectomy System, Designed to Address a Critical, Unmet Need by Facilitating Removal of Thrombi and Emboli Below the Knee | NASDAQ:SRDX | SurModics Inc |
| 16/01/2024 | 13:30 | Business Wire | Surmodics to Report First Quarter of Fiscal 2024 Financial Results on February 1 | NASDAQ:SRDX | SurModics Inc |
| 16/01/2024 | 13:30 | Business Wire | Surmodics to Host Virtual Annual Meeting of Shareholders | NASDAQ:SRDX | SurModics Inc |
